Minimal Residual Disease– tag –
-
Allogene Therapeutics’ TALEN-Edited Lymphoma Cell Therapy cema-cel Receives FDA RMAT and Fast Track Designations, Achieves 58.3% MRD Negativity in Phase 2 Trial
PRISM MarketView USA Overview Allogene Therapeutics' TALEN-edited allogeneic cell therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, accelerating its regulatory pa... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg... -
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients... -
ImmunoAct’s NexCAR19 Achieves 98% MRD Negativity in India with Significant Cost Reduction Compared to Western CAR-T Therapies
Citeline Scrip India Overview ImmunoAct's CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), achieved a 98% minimal residual disease (MRD) negativity rate in real-world Indian data, delivering comparable efficacy to Western CAR-T t... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (...
1